U.S. Department of Health and Human Services
Christopher Koh

 Contact Info

Tel: 301-443-9402
Email: kohchris@mail.nih.gov

 Select Experience

  • Gastroenterology FellowshipUniversity of Maryland School of Medicine, NIDDK, NIH2010-2013 
  • Hepatology FellowshipNIDDK, NIH2007-2010
  • Chief Medical ResidentHarbor Hospital2006-2007
  • Internal Medicine ResidencyHarbor Hospital2004-2007
  • M.H.Sc.Duke University School of Medicine2008-2012
  • M.D.Saba University School of Medicine2000-2004
  • Graduate Certificate in Healthcare AdministrationSeton Hall University1998-2000

 Related Links


Christopher Koh, M.D. M.H.Sc.

Staff Clinician, Liver Diseases Virology SectionLiver Diseases Branch
Director, University of Maryland/NIH Clinical Scholars Gastroenterology Fellowship Program
Co-Director, NIDDK Hepatology Fellowship Program


A selection of recent and significant publications can be viewed below.

Tang DM, Heller T, Koh C. The many faces of positive hepatitis B surface antigen. Hepatology. 2016 Feb 18; (2016 Feb 18). [Full Text/Abstract]
Morse CG, McLaughlin M, Proschan M, Koh C, Kleiner DE, Heller T, Kovacs JA. Transient elastography for the detection of hepatic fibrosis in HIV-monoinfected adults with elevated aminotransferases on antiretroviral therapy. AIDS. 2015 Nov; 29 (17; 2015 Nov; 29):2297-302. [Full Text/Abstract]
Feld JJ, Kato GJ, Koh C, Shields T, Hildesheim M, Kleiner DE, Taylor JG 6th, Sandler NG, Douek D, Haynes-Williams V, Nichols JS, Hoofnagle JH, Jake Liang T, Gladwin MT, Heller T. Liver injury is associated with mortality in sickle cell disease. Aliment Pharmacol Ther. 2015 Oct; 42 (7; 42; 2015 Oct):912-21. [Full Text/Abstract]
Koh C, Canini L, Dahari H, Zhao X, Uprichard SL, Haynes-Williams V, Winters MA, Subramanya G, Cooper SL, Pinto P, Wolff EF, Bishop R, Ai Thanda Han M, Cotler SJ, Kleiner DE, Keskin O, Idilman R, Yurdaydin C, Glenn JS, Heller T. Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial. Lancet Infect Dis. 2015 Jul 16; 15 (2015 Jul 16; 15; 10):1167-74. [Full Text/Abstract]
Kuehn HS, Ouyang W, Lo B, Deenick EK, Niemela JE, Avery DT, Schickel JN, Tran DQ, Stoddard J, Zhang Y, Frucht DM, Dumitriu B, Scheinberg P, Folio LR, Frein CA, Price S, Koh C, Heller T, Seroogy CM, Huttenlocher A, Rao VK, Su HC, Kleiner D, Notarangelo LD, Rampertaap Y, Olivier KN, McElwee J, Hughes J, Pittaluga S, Oliveira JB, Meffre E, Fleisher TA, Holland SM, Lenardo MJ, Tangye SG, Uzel G. Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4. Science. 2014 Sep 11; 345 (2014 Sep 11; 6204; 345):1623-7. [Full Text/Abstract]
Guedj J, Rotman Y, Cotler SJ, Koh C, Schmid P, Albrecht J, Haynes-Williams V, Liang TJ, Hoofnagle JH, Heller T, Dahari H. Understanding early serum hepatitis D virus and hepatitis B surface antigen kinetics during pegylated interferon-alpha therapy via mathematical modeling. Hepatology. 2014 Aug 7; 60 (6; 2014 Aug 7; 60):1902-10. [Full Text/Abstract]
Heller T, Rotman Y, Koh C, Clark S, Haynes-Williams V, Chang R, McBurney R, Schmid P, Albrecht J, Kleiner DE, Ghany MG, Liang TJ, Hoofnagle JH. Long-term therapy of chronic delta hepatitis with peginterferon alfa. Aliment Pharmacol Ther. 2014 Jul; 40 (40; 2014 Jul; 1):93-104. [Full Text/Abstract]
Sakiani S, Koh C, Heller T. Understanding The Presence of False Positive Antibodies in Acute Hepatitis. J Infect Dis. 2014 Jun 18; 210 (2014 Jun 18; 210; 12):1886-9. [Full Text/Abstract]
Koh C, Liang TJ. What is the future of ribavirin therapy for hepatitis C?. Antiviral Res. 2014 Apr; 104 (104; 2014 Apr):34-9. [Full Text/Abstract]
Hara K, Rivera MM, Koh C, Demino M, Page S, Nagabhyru PR, Rehermann B, Liang TJ, Hoofnagle JH, Heller T. Sequence Analysis of Hepatitis C Virus From Patients With Relapse After a Sustained Virological Response: Relapse or Reinfection?. J Infect Dis. 2014 Jan 1; 209 (209; 2014 Jan 1; 1):38-45. [Full Text/Abstract]
Koh C, Zhao X, Samala N, Sakiani S, Liang TJ, Talwalkar JA. AASLD clinical practice guidelines: A critical review of scientific evidence and evolving recommendations. Hepatology. 2013 Dec; 58 (6; 2013 Dec; 58):2142-52. [Full Text/Abstract]
Koh C, Turner T, Zhao X, Minniti CP, Feld JJ, Simpson J, Demino M, Conrey AK, Jackson MJ, Seamon C, Kleiner DE, Kato GJ, Heller T. Liver stiffness increases acutely during sickle cell vaso-occlusive crisis. Am J Hematol. 2013 Nov; 88 (2013 Nov; 11; 88):E250-4. [Full Text/Abstract]
Koh C, Heller T, Haynes-Williams V, Hara K, Zhao X, Feld JJ, Kleiner DE, Rotman Y, Ghany MG, Liang TJ, Hoofnagle JH. Long-term outcome of chronic hepatitis C after sustained virological response to interferon-based therapy. Aliment Pharmacol Ther. 2013 May; 37 (2013 May; 37; 9):887-94. [Full Text/Abstract]
Eccleston JL, Koh C, Markello TC, Gahl WA, Heller T. An apparent homozygous deletion in maltase-glucoamylase, a lesson in the evolution of SNP arrays. Mol Genet Metab. 2012 Dec; 107 (2012 Dec; 107; 4):674-8. [Full Text/Abstract]